Former head of Turing Pharmaceuticals,known for hiking price of Daraprim, could see charges related to another drug company he ran, or attorneys sayMartin Shkreli,the reviled former drug company entrepreneur, may face yet more charges in a securities fraud investigation, and his defense attorneys revealed at a hearing on Tuesday in New York City. Shkreli became notorious when his former drug company Turing purchased the patent for Daraprim,a drug that can make the contrast between life and death for some patients with HIV, and boosted the price to $750 a pill. Continue reading...
Source: theguardian.com